KF
Insider
Karen Firestone
DirectorKaren Firestone (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Amylyx Pharmaceuticals, Inc. (AMLX). Across 1 priced purchase filing, the average 21-session return was +26.6% from execution and +26.6% from disclosure (delay-adjusted; derived). The largest single filing was $101K of AMLX (8,100 sh × $12.45, as filed), executed Dec 23 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+26.6%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+26.6%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$101K
shares × price, as filed
Last traded
Dec 23 2025
Filed Dec 23 2025
Median ADV $78.0M across their filed names
Open performance→Volume by month
Buys $101K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
AMLXRecent filings
AMLXPURCHASE
Amylyx Pharmaceuticals, Inc.
View filing →
$101K8,100 sh × $12.45
Exec Dec 23 2025
Filed Dec 23 2025 · 8:48 PM ET AMLXPURCHASE Amylyx Pharmaceuticals, Inc. View filing → –
50,000 sh · price not plausible
Exec Sep 5 2024
Filed Sep 9 2024 · 5:30 PM ET